Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Meningioma, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No approved systemic therapy; grade 3 and recurrent unresectable tumours have few options.
Also on OnCo: Treatment journeys · Survivorship planner.
Whether completely resected grade 2 meningiomas need radiotherapy (ROAM, NRG BN003).
Which incidental meningiomas will grow; most never do.
Long-term cognitive and endocrine effects of radiotherapy to the skull base.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
Brigatinib produced radiographic responses in 10 percent of target tumours and 23 percent of all tumours, slowed growth of every tumour type and improved hearing in 35 percent of eligible ears in 40 heavily pretreated patients.
Six-month progression-free survival 83% (10 of 12) in grade 1 and 33% (8 of 24) in grade 2 to 3 NF2-mutant meningioma; both cohorts met the trial's decision criterion for promising activity.
A milestone in how this cancer is treated.
Sahm and colleagues (Lancet Oncology).
Clark and colleagues (Science) and Brastianos and colleagues (Nature Genetics).